MX2021013004A - Metodos y composiciones de imitadores de mir-10 y objetivos de los mismos. - Google Patents

Metodos y composiciones de imitadores de mir-10 y objetivos de los mismos.

Info

Publication number
MX2021013004A
MX2021013004A MX2021013004A MX2021013004A MX2021013004A MX 2021013004 A MX2021013004 A MX 2021013004A MX 2021013004 A MX2021013004 A MX 2021013004A MX 2021013004 A MX2021013004 A MX 2021013004A MX 2021013004 A MX2021013004 A MX 2021013004A
Authority
MX
Mexico
Prior art keywords
mir
compositions
methods
mimics
targets
Prior art date
Application number
MX2021013004A
Other languages
English (en)
Inventor
Seungil Ro
Original Assignee
Nevada Res & Innovation Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nevada Res & Innovation Corporation filed Critical Nevada Res & Innovation Corporation
Publication of MX2021013004A publication Critical patent/MX2021013004A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a métodos y composiciones que comprenden un imitador miR-10a-5p o miR-10b-5p para tratamiento de trastornos de motilidad gastrointestinal, obesidad y diabetes.
MX2021013004A 2019-04-24 2020-04-24 Metodos y composiciones de imitadores de mir-10 y objetivos de los mismos. MX2021013004A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962837988P 2019-04-24 2019-04-24
US202062964382P 2020-01-22 2020-01-22
PCT/US2020/029807 WO2020219872A1 (en) 2019-04-24 2020-04-24 METHODS AND COMPOSITIONS OF MiR-10 MIMICS AND TARGETS THEREOF

Publications (1)

Publication Number Publication Date
MX2021013004A true MX2021013004A (es) 2022-03-04

Family

ID=72941232

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021013004A MX2021013004A (es) 2019-04-24 2020-04-24 Metodos y composiciones de imitadores de mir-10 y objetivos de los mismos.

Country Status (10)

Country Link
US (1) US20220211742A1 (es)
EP (1) EP3959317A4 (es)
JP (1) JP2022530031A (es)
KR (1) KR20220004989A (es)
CN (1) CN113950528A (es)
AU (1) AU2020263502A1 (es)
BR (1) BR112021021310A2 (es)
CA (1) CA3137897A1 (es)
MX (1) MX2021013004A (es)
WO (1) WO2020219872A1 (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201302468D0 (en) * 2013-02-12 2013-03-27 Reneuron Ltd Stem cell product
CA2880833A1 (en) * 2012-08-03 2014-02-06 Aptamir Therapeutics, Inc. Cell-specific delivery of mirna modulators for the treatment of obesity and related disorders
CN107075515B (zh) * 2013-11-22 2020-10-30 米纳治疗有限公司 C/EBPα组合物和使用方法

Also Published As

Publication number Publication date
KR20220004989A (ko) 2022-01-12
JP2022530031A (ja) 2022-06-27
EP3959317A4 (en) 2023-10-18
BR112021021310A2 (pt) 2021-12-14
CA3137897A1 (en) 2020-10-29
WO2020219872A1 (en) 2020-10-29
US20220211742A1 (en) 2022-07-07
EP3959317A1 (en) 2022-03-02
CN113950528A (zh) 2022-01-18
AU2020263502A1 (en) 2021-10-28

Similar Documents

Publication Publication Date Title
PH12018500086A1 (en) Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
MX2021015632A (es) Moduladores del receptor arilo y metodos para elaborar y usar los mismos.
BR112016029713A2 (pt) métodos para o tratamento de sobrepeso ou obesidade
JOP20210253A1 (ar) أجسام مضادة ذات سلسلة ثقيلة ترتبط بـ psma
WO2016061456A3 (en) Compositions and methods for identification, assessment, prevention, and treatment of t-cell exhaustion using cd39 biomarkers and modulators
NZ735044A (en) Condensed ring derivative, and preparation method, intermediate, pharmaceutical composition and use thereof
MX2022000397A (es) Inhibidores peptídicos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias.
CR20210545A (es) Formas sólidas de un inhibidor de glyt1
MX2022000632A (es) Cauchos de dieno terminados en carboxi.
MX2020006510A (es) Peptido novedoso.
MX2021001520A (es) Metodos para retardar la ocurrencia de diabetes tipo 2 de nuevo inicio y para desacelerar el progreso de y tratamiento de la diabetes tipo 2.
TR201909078T4 (tr) Kimyasal bileşikler ve bunların kas kalitesinin iyileştirilmesine yönelik kullanımı.
ZA202105101B (en) Peptides for treatment and prevention of diabetes and associated disorders
MX2021013004A (es) Metodos y composiciones de imitadores de mir-10 y objetivos de los mismos.
PH12020550050A1 (en) Novel acylated insulin analogues and uses thereof
WO2018236086A3 (ko) 신규한 에로모나스 하이드로필라 박테리오파지 Aer-HYP-2 및 이의 에로모나스 하이드로필라 균 증식 억제 용도
WO2018148629A3 (en) Methods and compositions for treating neurodegeneration and fibrosis
AU2017247612A9 (en) Hafnia alvei based pharmaceutical and food compositions for inducing satiation and prolonging satiety
MX2018007212A (es) Peptidos dieteticos.
MX2021001393A (es) Composiciones para el tratamiento de la enfermedad de injerto contra huesped.
GB2574747A (en) Use of lambda interferons in the treatment of obesity-related disorders and related diseases
MX2019002647A (es) Composiciones de tesofensina.
WO2016188932A3 (en) Combination of trpm8-agonist and nachr-agonist for treatment of obesity and related disorders and for weight reduction
WO2022036140A3 (en) Klf11 sirna for treatment of diabetes and obesity
MX2014015450A (es) Una composicion simbiotica sinérgica y su uso para el tratamiento de la disbiosis intestinal.